Here is the design of a clinical trial:

Official Title: Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults

Included conditions:
- Type 1 Diabetes

Study Armgroups:
- {'label': 'Victoza®', 'type': 'ACTIVE_COMPARATOR', 'description': 'Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)', 'interventionNames': ['Drug: Victoza®']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Victoza®', 'description': 'Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.', 'armGroupLabels': ['Victoza®']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': 'FPIR (first phase insulin response)', 'description': 'First phase insulin response during 10-min IVGTT (intravenous glucose tolerance test )', 'timeFrame': 'From baseline to 26 and 104 weeks'}

Please estimate the sample size based on the assumption: 
Significance level (alpha) of 0.05, power of 80%, and a dropout rate of 10% initially, later adjusted to a 20% dropout rate.
2.10
        Sample size
        Based on reference values reported earlier, we expected that in stage 1 and stage 2 trials, 6Â months after randomisation, FPIR mean would be 46 (SD 15) and 40 (SD 15) mU/L in placebo groups, respectively.
24
 For stage 3 trial, Câpeptide AUC in 2âh MMTT was assumed to be 1.0Â nmol/L/120âmin (SD 0.3) after 6Â months from early diagnosis of type 1 diabetes in the placebo group. This was based on Câpeptide AUC data in 2âh OGTT at diagnosis in the DPTâ1 study.
26
 Thus, sample sizes of 42, 54 and 14 participants in stage 1, 2 and 3 trials, respectively, would give an 80% probability to observe a 30% higher FPIR in 10âmin IVGTT and 50% higher Câpeptide AUC in 2âh MMTT in the liraglutide groups as compared with the placebo groups when using twoâsided tâtests given alpha 0.05 and 10% dropout. However, our early observations from still blinded stage 1 and 2 trials indicated that some participants had marked increases of 100% to 360% in FPIR whereas others had stable or declining FPIR. Therefore, we supposed that the remarkable increase in FPIR had occurred in the participants receiving active investigational product and recalculated the sample size under the assumption of 100% increase after liraglutide treatment, and sample sizes of 10 participants to be randomised in stage 1 and 2 trials were found to be sufficient to detect a clinically significant difference even when assuming a dropout rate of 20%. The participants who withdraw from the study before visit 4 will be replaced and randomised as a new participant. However, data from all randomised participants will be included in the intention to treat analyses.